Understanding the Key Differences Between Biopharmaceuticals Pharmacokinetics (PK) and Pharmacodynamics (PD)

Biopharmaceuticals, often derived from living organisms, have revolutionized the treatment of various diseases, offering targeted and effective therapies. However, understanding their behavior in the body requires a deep dive into two critical areas: pharmacokinetics (PK) and pharmacodynamics (PD). These disciplines, while interconnected, focus on different aspects of drug action and are essential for optimizing therapeutic outcomes. Additionally, immunogenicity, the ability of a substance to provoke an immune response, plays a significant role in both PK and PD of biopharmaceuticals.

Pharmacokinetics (PK): What the Body Does to the Drug

Pharmacokinetics involves studying how a drug is absorbed, distributed, metabolized, and excreted by the body. These processes are collectively known as ADME:

1. Absorption: This is the process by which a drug enters the bloodstream from the administration site. Absorption can be complex for biopharmaceuticals due to their large molecular size and the need for specific delivery mechanisms¹.
2. Distribution: Once in the bloodstream, the drug is distributed to various tissues and organs. Biopharmaceuticals’ distribution is influenced by molecular size, charge, and binding to plasma proteins².
3. Metabolism: Biopharmaceuticals are often metabolized differently compared to small-molecule drugs. They may undergo proteolytic degradation or be processed by the reticuloendothelial system³.
4. Excretion: The elimination of biopharmaceuticals can occur through renal excretion or via the liver. The large size of these molecules often means they are broken down into smaller fragments before excretion⁴.

Pharmacodynamics (PD): What the Drug Does to the Body

Pharmacodynamics focuses on drugs’ biochemical and physiological effects and their mechanisms of action. For biopharmaceuticals, PD involves understanding how these drugs interact with their targets, such as receptors or enzymes, to produce a therapeutic effect⁵.

1. Mechanism of Action: Biopharmaceuticals often work by mimicking or inhibiting natural biological processes. For example, monoclonal antibodies can block specific receptors on cancer cells, preventing their growth.
2. Dose-Response Relationship: This describes how the drug’s effect changes with varying doses. Biopharmaceuticals can exhibit non-linear dose-response relationships due to factors like receptor saturation.
3. Therapeutic Window: The range of drug concentrations in which a biopharmaceutical is effective without toxicity. This window can be narrow, requiring precise dosing and monitoring.

                          Figure 1. Relationship between drug and effect.

The Cost of Drug Development and the Role of PK/PD

Drug development is expensive and time-consuming, often costing billions of dollars and taking over a decade to bring a new drug to market. PK and PD studies play a pivotal role in this process by providing critical data that can streamline development and reduce costs. Early PK/PD studies can identify potential issues with drug candidates, such as poor absorption or undesirable side effects, allowing for early modifications or discontinuation of problematic compounds ^2,4. Focusing on the most promising candidates can save significant time and resources.

Immunogenicity: A Critical Factor in PK and PD

Immunogenicity refers to a biopharmaceutical’s ability to elicit an immune response, which can significantly impact PK and PD ^8,9

1. Impact on PK: Immunogenicity can alter a drug’s pharmacokinetics by accelerating its clearance from the body. The formation of anti-drug antibodies (ADAs) can rapidly remove the drug, reducing its efficacy⁸.
2. Impact on PD: Immunogenicity can also affect pharmacodynamics by neutralizing the drug’s activity. ADAs can bind to the drug, preventing it from interacting with its target and thereby diminishing its therapeutic effect⁹.
3. Clinical Implications: Biopharmaceuticals’ immunogenicity can lead to adverse effects such as allergic reactions or loss of efficacy. Monitoring and managing immunogenicity is crucial for these therapies’ safe and effective use⁹.

          Figure 2. The impact of Immunogenicity on PK/PD: Clinical ramifications

Critical Differences Between PK and PD in Biopharmaceuticals

While PK and PD are distinct areas of study, they are closely related, and both are essential for understanding the overall behavior of biopharmaceuticals in the body ^6,7.

1. Focus: PK is concerned with the drug’s journey through the body (absorption, distribution, metabolism, excretion), whereas PD focuses on the drug’s effects on the body (mechanism of action, dose-response, therapeutic window)⁷.
2. Measurement: PK parameters are typically measured using blood plasma concentrations over time, while PD parameters are assessed through the drug’s biological effects, such as changes in biomarkers or clinical outcomes⁶.
3. Interdependence: A biopharmaceutical’s PK profile can influence PD effects. For example, a drug with poor absorption may not reach therapeutic levels, affecting its efficacy ^6,7.
4. Complexity in Biopharmaceuticals: Biopharmaceuticals’ sizeable molecular size and complex structure complicate PK and PD studies. Immunogenicity, target-mediated drug disposition, and non-linear kinetics are more pronounced in biopharmaceuticals than in small-molecule drugs^7,8,9.

Conclusion

Understanding the critical differences between pharmacokinetics and pharmacodynamics, along with the role of immunogenicity, is crucial for the development and clinical use of biopharmaceuticals. These insights help design effective dosing regimens, predict therapeutic outcomes, and manage potential adverse effects. As biopharmaceuticals continue to evolve, ongoing research in PK and PD will be essential to harness their therapeutic potential fully.

1. Talevi, A., Quiroga, P.A.M. (2018). Introduction. Biopharmaceutics and Pharmacokinetics. In: Talevi, A., Quiroga, P. (eds) ADME Processes in Pharmaceutical Sciences. Springer, Cham. https://doi.org/10.1007/978-3-319-99593-9_1
2. Guenther Hochhaus PhD, FCP, Dr. Jeffrey S. Barrett PhD, FCP, Hartmut Derendorf PhD, FCP. Evolution of Pharmacokinetics and Pharmacokinetic/Dynamic Correlations during the 20th Century. J. of Clin. Pharmacology, 08 March 2013. https://accp1.onlinelibrary.wiley.com/doi/10.1177/00912700022009648
3. Nancy P. Barbour & Robert A. Lipper, Introduction to Biopharmaceutics and its Role in Drug Development. https://link.springer.com/chapter/10.1007/978-0-387-72379-2_1#auth-Nancy_P_-Barbour
4. Pallavi M. Chaudhari, Pranav Shah, Harita Desai, Neha Raghuvanshi & Bhagwat Patil. Biosimilars in Clinical Trials. https://link.springer.com/chapter/10.1007/978-981-97-3001-8_14#citeas
5. Dennis A Smith 1, Li Di, Edward H Kerns, The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat Rev Drug Discov. 2010 Dec;9(12):929-39. https://pubmed.ncbi.nlm.nih.gov/21119731/#:~:text=doi%3A%2010.1038/nrd3287
6. European Medicines Agency. Guideline on Similar Biological Medicinal Products Containing Monoclonal Antibodies—Non-Clinical and Clinical Issues, 2022. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128686.pdf
7. Kaur P, Chow V, Zhang N, Moxness M, Kaliyaperumal A, Markus R (2017) A randomized, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab. Ann Rheum Dis 76:526–533. https://doi.org/10.1136/annrheumdis-2015-208914
8. Alison Smith, Hugh Manoli, Stacey Jaw, Kimberley Frutoz, Alan L. Epstein, Leslie A. Khawli, and Frank-Peter Theil, 2016. Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins. J. of Immuno. Res, Vol. 2016, Article ID 2342187, 9 pgs. http://dx.doi.org/10.1155/2016/2342187
9. Narendra Chirmule, Vibha Jawa, and Bernd Meibohm, Immunogenicity to Therapeutic Proteins: Impact on PK/PD and Efficacy. The AAPS Journal, Vol. 14, No. 2, June 2012 (# 2012), http://doi: 10.1208/s12248-012-9340-y